Mitchell R Knisely1, Janet S Carpenter2, Claire Burke Draucker3, Todd Skaar4, Marion E Broome5, Ann M Holmes6, Diane Von Ah7. 1. Department of Health Promotion & Development, School of Nursing, University of Pittsburgh, 3500 Victoria Street, 360D, Pittsburgh, PA 15261, United States. Electronic address: mik126@pitt.edu. 2. Science of Nursing Care Department, School of Nursing, Indiana University, 600 Barnhill Drive, NU 340G, Indianapolis, IN 46202, United States. 3. Community and Health Systems Department, School of Nursing, Indiana University, 600 Barnhill Drive, NU W409, Indianapolis, IN 46202, United States. 4. Division of Clinical Pharmacology, Department of Medicine, School of Medicine, Indiana University, 950 W. Walnut St., Research II Room E402, Indianapolis, IN 46202, United States. 5. School of Nursing, Duke University, 307 Trent Dr., 4142 Pearson Bldg., Durham, NC 27710, United States. 6. Health Policy & Management, School of Public Health, Indiana University, 1050 Wishard Blvd., RG 5138, Indianapolis, IN 46202, United States. 7. Community & Health Systems Department, School of Nursing, Indiana University, 600 Barnhill Drive, NU 407, Indianapolis, IN 46202, United States.
Abstract
PURPOSE: When codeine and tramadol are used for pain management, it is imperative that nurses are able to assess for potential drug-gene and drug-drug-gene interactions that could adversely impact drug metabolism and ultimately pain relief. Both drugs are metabolized through the CYP2D6 metabolic pathway which can be affected by medications as well the patient's own pharmacogenotype. The purpose of this brief report is to identify drug-gene and drug-drug-gene interactions in 30 adult patients prescribed codeine or tramadol for pain. METHODS: We used three data sources: (1) six months of electronic health record data on the number and types of medications prescribed to each patient; (2) each patient's CYP2D6 pharmacogenotype, and (3) published data on known CYP2D6 gene-drug and drug-drug-gene interactions. RESULTS: Ten patients (33%) had possible drug-gene or drug-drug-gene interactions. Five patients had CYP2D6 drug-gene interactions indicating they were not good candidates for codeine or tramadol. In addition, five patients had potential CYP2D6 drug-drug-gene interactions with either codeine or tramadol. CONCLUSION: Our findings from this exploratory study underscores the importance of assessing and accounting for drug-gene and drug-drug-gene interactions in patients prescribed codeine or tramadol.
PURPOSE: When codeine and tramadol are used for pain management, it is imperative that nurses are able to assess for potential drug-gene and drug-drug-gene interactions that could adversely impact drug metabolism and ultimately pain relief. Both drugs are metabolized through the CYP2D6 metabolic pathway which can be affected by medications as well the patient's own pharmacogenotype. The purpose of this brief report is to identify drug-gene and drug-drug-gene interactions in 30 adult patients prescribed codeine or tramadol for pain. METHODS: We used three data sources: (1) six months of electronic health record data on the number and types of medications prescribed to each patient; (2) each patient's CYP2D6 pharmacogenotype, and (3) published data on known CYP2D6 gene-drug and drug-drug-gene interactions. RESULTS: Ten patients (33%) had possible drug-gene or drug-drug-gene interactions. Five patients had CYP2D6 drug-gene interactions indicating they were not good candidates for codeine or tramadol. In addition, five patients had potential CYP2D6 drug-drug-gene interactions with either codeine or tramadol. CONCLUSION: Our findings from this exploratory study underscores the importance of assessing and accounting for drug-gene and drug-drug-gene interactions in patients prescribed codeine or tramadol.
Authors: J K Hicks; J R Bishop; K Sangkuhl; D J Müller; Y Ji; S G Leckband; J S Leeder; R L Graham; D L Chiulli; A LLerena; T C Skaar; S A Scott; J C Stingl; T E Klein; K E Caudle; A Gaedigk Journal: Clin Pharmacol Ther Date: 2015-06-29 Impact factor: 6.875
Authors: Brian Thomas Hocum; John Raymond White; Jarrod W Heck; Ranjit K Thirumaran; Nicolas Moyer; Richard Newman; Kristine Ashcraft Journal: Am J Health Syst Pharm Date: 2016-01-15 Impact factor: 2.637
Authors: Carl A Anderson; Fredrik H Pettersson; Geraldine M Clarke; Lon R Cardon; Andrew P Morris; Krina T Zondervan Journal: Nat Protoc Date: 2010-08-26 Impact factor: 13.491
Authors: Silvana Borges; Zeruesenay Desta; Yan Jin; Azzouz Faouzi; Jason D Robarge; Sanosh Philips; Santosh Philip; Anne Nguyen; Vered Stearns; Daniel Hayes; James M Rae; Todd C Skaar; David A Flockhart; Lang Li Journal: J Clin Pharmacol Date: 2010-01-15 Impact factor: 3.126
Authors: K D Levy; B S Decker; J S Carpenter; D A Flockhart; P R Dexter; Z Desta; T C Skaar Journal: Clin Pharmacol Ther Date: 2014-05-07 Impact factor: 6.875
Authors: K R Crews; A Gaedigk; H M Dunnenberger; J S Leeder; T E Klein; K E Caudle; C E Haidar; D D Shen; J T Callaghan; S Sadhasivam; C A Prows; E D Kharasch; T C Skaar Journal: Clin Pharmacol Ther Date: 2014-01-23 Impact factor: 6.875
Authors: Emily J Cicali; D Max Smith; Benjamin Q Duong; Lukas G Kovar; Larisa H Cavallari; Julie A Johnson Journal: Clin Pharmacol Ther Date: 2020-02-13 Impact factor: 6.875
Authors: Cathy R Fulton; Yong Zang; Zeruesenay Desta; Marc B Rosenman; Ann M Holmes; Brian S Decker; Yifei Zhang; John T Callaghan; Victoria M Pratt; Kenneth D Levy; Brandon T Gufford; Paul R Dexter; Todd C Skaar; Michael T Eadon Journal: Pharmacogenomics Date: 2019-02-20 Impact factor: 2.533
Authors: Emily J Cicali; Amanda L Elchynski; Kelsey J Cook; John T Houder; Cameron D Thomas; D Max Smith; Amanda Elsey; Julie A Johnson; Larisa H Cavallari; Kristin Wiisanen Journal: Clin Pharmacol Ther Date: 2021-07-28 Impact factor: 6.903
Authors: C Jeiziner; K Suter; U Wernli; J M Barbarino; L Gong; M Whirl-Carrillo; T E Klein; T D Szucs; K E Hersberger; H E Meyer Zu Schwabedissen Journal: Pharmacogenomics J Date: 2020-10-17 Impact factor: 3.550